Cibinqo (abrocitinib) is used to treat moderate-to-severe atopic dermatitis (also known as eczema) in adults and children ages 12 years and older. It's taken by mouth, typically once daily. Cibinqo (abrocitinib) isn't a first-choice option for this condition because it has a FDA black box warning for the potential to cause serious side effects, such as cancer and infections. Some of the more common side effects of this medication include nausea, cold symptoms, and headaches.
Cibinqo (abrocitinib) is a Janus kinase (JAK) inhibitor. It blocks an enzyme (protein) called JAK in the body that plays a role in inflammation. By stopping this enzyme from working, Cibinqo (abrocitinib) lowers inflammation to relieve symptoms of atopic dermatitis.
The following side effects may get better over time as your body gets used to the medication. Let your healthcare provider know immediately if you continue to experience these symptoms or if they worsen over time.
Contact your healthcare provider immediately if you experience any of the following.
Side effects that you should report to your care team as soon as possible:
Side effects that usually do not require medical attention (report these to your care team if they continue or are bothersome):
Cibinqo (abrocitinib) works pretty well to treat eczema. In clinical studies, about 40% to 60% of adults and about 70% of children at least 12 years old who took Cibinqo (abrocitinib) had at least a 75% improvement in their skin symptoms after 3 months. In comparison, only 11% of the adults and 42% of children who received placebo had the same results.
It depends. You should avoid taking Cibinqo (abrocitinib) with other medications that can weaken your immune system, including other immunosuppressant eczema medications. Taking this combination of medications can raise your risk of infection. But the manufacturer of Cibinqo (abrocitinib) notes that if needed, it can be taken with topical corticosteroids. Make sure you check with your provider before you start any new medications so they can help you look for medication interactions.
No, Cibinqo (abrocitinib) isn't considered a biologic. Biologics are medications made from living sources, like cells. Cibinqo (abrocitinib) is a synthetic (man-made) medication that belongs to the JAK inhibitor class of medications.
No, Cibinqo (abrocitinib) doesn't appear to cause weight changes. In clinical studies, people taking Cibinqo (abrocitinib) didn't report weight gain or weight loss.
Cibinqo (abrocitinib) hasn't been well-studied in human pregnancies, but animal studies suggest that it might cause harm if taken during pregnancy. If you're pregnant or thinking of getting pregnant, talk to your provider to see if Cibinqo (abrocitinib) is right for you. If you're pregnant and are prescribed Cibinqo (abrocitinib) or if you become pregnant while receiving treatment, it's recommended that you enroll in the Cibinqo pregnancy registry by calling 1-877-311-3770.
You should avoid taking Cibinqo (abrocitinib) while nursing and for at least 1 day after your last dose. There's a possibility that this medication can pass through breastmilk and cause harm to a nursing baby. Talk to your provider about safer ways to ease eczema symptoms while nursing.
Cibinqo (abrocitinib) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.
Cibinqo (abrocitinib) can affect your body's ability to fight off infections. This can raise your risk of serious bacterial (e.g., tuberculosis (TB)), viral (e.g., herpes, hepatitis), or fungal infections. Your provider will routinely monitor you for infections before and during treatment with Cibinqo (abrocitinib). If you notice any signs of infection during treatment like fever, chills, body aches, or cough, let your provider know right away.
Though this hasn't been seen with Cibinqo (abrocitinib), use of JAK inhibitors for rheumatoid arthritis has been linked to higher risk of death for some people, such as older adults with at least one heart-related risk factor. Talk to your provider about the risks and benefits of using Cibinqo (abrocitinib) before you start treatment.
Some people who took JAK inhibitors reported they developed cancer during treatment. These cancers included lymphoma and skin cancer. Some cancers have been reported by people taking Cibinqo (abrocitinib) during clinical studies. Because of this, your provider will monitor you for your risk of cancer during treatment. Additionally, make sure you schedule yearly screenings for skin cancer and let your provider know if you notice changes to your skin. Wear protective clothing and use sunscreen if you're out in the sun, and avoid UV light (e.g., tanning beds) to lower your risk of skin cancer.
People who took JAK inhibitors reported blood clots in various parts of the body, including the heart and brain. While these conditions haven't been linked to Cibinqo (abrocitinib), these risks are still possible. Get medical help right away if you experience symptoms of blood clots, such as the following.
Legs (deep vein thrombosis): leg cramp, swelling, pain, muscle tightness Lungs (pulmonary embolism): cough, chest pain, trouble breathing, racing heart Heart (arterial thrombosis): chest pain, short of breath, pain in the jaw, neck, or back, feeling weak or light-headed Brain (stroke): sudden weakness in your body, trouble speaking, confusion, dizziness Eyes: vision changes, pain
Cibinqo (abrocitinib) can lower the number of red blood cells (RBCs), white blood cells (WBCs), and platelets in your body. This can raise your risk for bleeds, anemia, and infections. Your provider might order blood draws to check your blood cell counts. Let your provider know if you experience possible symptoms of low blood cell counts, such as the following.
Bleeds (low platelet count): small, flat red spots under your skin, blood in your urine or stool, easy bleeding or bruising Anemia (low RBC count): feeling tired, headache, pale skin, fast heart rate, trouble breathing Infections (low WBC count): fever, chills, tiredness, cough, body aches, runny nose
Cibinqo (abrocitinib) can raise your cholesterol levels. Your provider will order cholesterol tests regularly while you're taking Cibinqo (abrocitinib). Let your provider know if you have high cholesterol, or are taking medications for high cholesterol, before starting Cibinqo (abrocitinib).
| Dosage | Quantity | Price as low as | Price per unit |
|---|---|---|---|
| 100mg | 30 tablets | $5,690.91 | $189.70 |
| 200mg | 30 tablets | $5,926.76 | $197.56 |
| 50mg | 30 tablets | $5,321.82 | $177.39 |
The typical starting dose is 100 mg by mouth once a day. Your provider might raise your dose to 200 mg once a day if your skin symptoms haven't improved after 3 months.
Your dose might differ if you have kidney problems, if you're taking a medication that interacts with Cibinqo (abrocitinib), if your body breaks down Cibinqo (abrocitinib) poorly based on genetic testing, or if you're having side effects.
Contraindications are specific health conditions or situations in which a person should not take a medication due to safety concerns. If you have any of the following conditions or if any of the following apply to you, let your healthcare provider know because Cibinqo (abrocitinib) will not be safe for you to take.
Moderate-to-severe inflammatory conditions in which other treatments haven't worked: